RxDoctor Payments Data

Manuel Izquierdo, DO

Critical Care Medicine · Simpsonville, SCNPI 1871972877

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Merck accounts for 61.7% of it on its own, with 11 other manufacturers making up the rest.

$2,171in general payments, 2019–2025

Across 57 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Electromed, Inc.$230
  • Verona Pharma, Inc.$162
  • Insmed, Inc.$125
  • AstraZeneca$68
  • Baxter Healthcare$67
  • plus $179 from 6 others

What the payments were for

  • Consulting fees$1,30060%
  • Food & beverage$80937%
  • Education$623%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,171 in reported general payments places this provider in the 70th percentile of 93 critical care medicine providers in South Carolina.

See all critical care medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$86,462
Medicare patients
293
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft38$996,029
OfevNintedanib Esylate14$179,999
CaystonAztreonam Lysine13$159,246
NucalaMepolizumab28$103,780
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$68,439
ZenpepLipase/Protease/Amylase13$61,552
CreonLipase/Protease/Amylase14$35,662
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$20,213
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$17,329
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$15,931
Breo ElliptaFluticasone/Vilanterol37$15,364
Spiriva RespimatTiotropium Bromide29$14,886
Incruse ElliptaUmeclidinium Bromide29$12,198
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate40$8,953
SymbicortBudesonide/Formoterol Fumarate18$6,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$23$996,02938 claims
GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$52$217,110227 claims
AstraZenecaBreztri Aerosphere, Symbicort$68$21,93245 claims
MerckDulera$1,340$4,18713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 93 critical care medicine providers in South Carolina.

Other critical care medicine in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →